Compare Incyte Corporation (INCY) vs IONQ Inc (IONQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs IONQ Inc — how do they compare? Incyte Corporation trades at $113.13 (market cap $22.85B), while IONQ Inc trades at $39.94 (market cap $15.98B). The key difference: Incyte Corporation is the larger of the two by market cap, and Incyte Corporation is trading nearer its 52-week high, IONQ Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and IONQ Inc for 33 Days on average.
| INCY | IONQ | |
|---|---|---|
Market Cap | $22.85B | $15.98B |
Volume | 1,927,029 | 22,848,240 |
Sector | Health | Technology |
52-Week High | $129.93 | $82.09 |
52-Week Low | $83.80 | $26.59 |
Typical Hold Time | 33 Days | 33 Days |
Enterprise Value | $18.35B | $13.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
IONQ trades at $39.63, down 4.14% today, with a bearish technical signal despite oscillators showing some bullish momentum. The company reported revenue of $130.02M in 2025 but posted a net loss of $510.38M, reflecting negative profit margins of -553.27%. Recent earnings showed mixed results with a Q2 2026 miss after two consecutive beats. Analyst sentiment remains divided with a 50/50 buy/hold split but a consensus price target of $62.75 suggesting significant upside potential from current levels.
The outlook for IONQ hinges on scaling quantum computing technology to justify its premium valuation (P/S 54.74). While strong revenue growth projections and strategic partnerships offer long-term potential, investors face substantial risks from persistent losses, cash burn, and intense competition in the emerging quantum computing sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About IONQ Inc
IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.
Read more on IONQ →
